What is the recommended Pap (Papanicolaou) smear screening schedule for a female patient between 21 and 65 years old with a normal immune system and no history of cervical cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pap Smear Screening Schedule for Women Ages 21-65

For women aged 21-29 years, perform Pap testing alone every 3 years; for women aged 30-65 years, perform co-testing with Pap plus HPV testing every 5 years (preferred) or Pap testing alone every 3 years (acceptable). 1

Age-Specific Screening Protocols

Women Ages 21-29 Years

  • Begin screening at age 21 years, regardless of age of sexual debut or other risk factors 1
  • Screen every 3 years with conventional or liquid-based Pap test alone 1
  • Do NOT use HPV testing in this age group for routine screening, as HPV infections are common and typically transient in younger women 2
  • Do NOT screen women under age 21, even if sexually active 2, 3

Women Ages 30-65 Years

  • Preferred approach: Co-testing with Pap plus HPV DNA test every 5 years 1, 2
  • Acceptable alternative: Pap test alone every 3 years 1
  • The 5-year interval with co-testing is supported by the increased sensitivity of the combined approach 2

When to Stop Screening

Women Over Age 65

Discontinue screening if adequate prior negative screening is documented: 1

  • ≥3 consecutive negative Pap tests alone within the last 10 years, with the most recent test within the last 5 years, OR
  • ≥2 consecutive negative co-tests (Pap plus HPV) within the last 10 years, with the most recent test within the last 5 years

Post-Hysterectomy

  • Stop screening if the cervix was removed and there is no history of high-grade precancerous lesions (CIN2 or higher) or cervical cancer 1, 2

Critical Exceptions Requiring Modified Screening

History of Abnormal Results

  • Women with history of CIN2, CIN3, or adenocarcinoma in situ must continue screening for at least 20 years after treatment, even if this extends past age 65 4
  • Women with lower-grade abnormalities must demonstrate adequate negative screening AFTER resolution before standard cessation criteria apply 4

Immunocompromised Status

  • Women with HIV, transplant recipients, or chronic immunosuppression require annual screening indefinitely, regardless of age 5
  • These patients are explicitly excluded from standard screening guidelines and should never discontinue screening based on age alone 5

Common Pitfalls to Avoid

  • Avoid annual screening in average-risk women, as this increases costs and harms without meaningful benefit 2, 3
  • Avoid screening before age 21, as cervical cancer is extremely rare in this age group and screening leads to overtreatment 3
  • Avoid discontinuing screening prematurely in women with prior abnormal results or immunosuppression 5, 4
  • Avoid using HPV testing alone in women under age 30, as it has poor specificity in this population 2
  • Avoid screening after total hysterectomy with cervix removal in women without history of high-grade lesions 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cervical Cancer Screening Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cervical cancer screening among women aged 18-30 years - United States, 2000-2010.

MMWR. Morbidity and mortality weekly report, 2013

Guideline

Cervical Cancer Screening Guidelines for Women with Abnormal Pap History

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cervical Cancer Screening in HIV-Positive Individuals

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.